These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 11051272)

  • 21. Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma. A Gynecologic Oncology Group Study.
    Hoffman MA; Blessing JA; Morgan M
    Gynecol Oncol; 2000 Dec; 79(3):463-5. PubMed ID: 11104620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumors and their microenvironments: tilling the soil. Commentary re: A. M. Scott et al., A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res., 9: 1639-1647, 2003.
    Cheng JD; Weiner LM
    Clin Cancer Res; 2003 May; 9(5):1590-5. PubMed ID: 12738710
    [No Abstract]   [Full Text] [Related]  

  • 23. Effect of lonidamine on the aerobic glycolysis of normal and phytohemagglutinin-stimulated human peripheral blood lymphocytes.
    Nista A; De Martino C; Malorni W; Marcante ML; Silvestrini B; Floridi A
    Exp Mol Pathol; 1985 Apr; 42(2):194-205. PubMed ID: 3156759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heat shock protein 27, a novel regulator of 5-fluorouracil resistance in colon cancer.
    Tsuruta M; Nishibori H; Hasegawa H; Ishii Y; Endo T; Kubota T; Kitajima M; Kitagawa Y
    Oncol Rep; 2008 Nov; 20(5):1165-72. PubMed ID: 18949417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lonidamine: an innovative therapy in oncology.
    Semin Oncol; 1991 Apr; 18(2 Suppl 4):1-72. PubMed ID: 2031190
    [No Abstract]   [Full Text] [Related]  

  • 26. Correspondence re: T. Fehm et al., Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin. Cancer Res., 8: 2073-2084, 2002.
    Fiegl M; Kircher B; Zojer N
    Clin Cancer Res; 2003 Mar; 9(3):1224-5; author reply 1226. PubMed ID: 12631629
    [No Abstract]   [Full Text] [Related]  

  • 27. Modulation of glycolysis in neuroepithelial tumors.
    Floridi A; Paggi MG; Fanciulli M
    J Neurosurg Sci; 1989; 33(1):55-64. PubMed ID: 2674359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blocking CD147 induces cell death in cancer cells through impairment of glycolytic energy metabolism.
    Baba M; Inoue M; Itoh K; Nishizawa Y
    Biochem Biophys Res Commun; 2008 Sep; 374(1):111-6. PubMed ID: 18616931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma.
    Ndozangue-Touriguine O; Sebbagh M; Mérino D; Micheau O; Bertoglio J; Bréard J
    Oncogene; 2008 Oct; 27(46):6012-22. PubMed ID: 18560353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lonidamine in malignant brain tumors.
    Schiffer D; Sales S; Soffietti R
    Semin Oncol; 1991 Apr; 18(2 Suppl 4):38-41. PubMed ID: 2031197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of all-trans retinoic acid on drug sensitivity and expression of survivin in LoVo cells.
    Wei HB; Hu BG; Han XY; Zheng ZH; Wei B; Huang JL
    Chin Med J (Engl); 2008 Feb; 121(4):331-5. PubMed ID: 18304466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Silencing hexokinase II gene sensitizes human colon cancer cells to 5-fluorouracil.
    Peng Q; Zhou J; Zhou Q; Pan F; Zhong D; Liang H
    Hepatogastroenterology; 2009; 56(90):355-60. PubMed ID: 19579598
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mammalian target of rapamycin promotes vincristine resistance through multiple mechanisms independent of maintained glycolytic rate.
    Vanderweele DJ; Rudin CM
    Mol Cancer Res; 2005 Nov; 3(11):635-44. PubMed ID: 16317089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The anti-trypanosomal agent lonidamine inhibits Trypanosoma brucei hexokinase 1.
    Chambers JW; Fowler ML; Morris MT; Morris JC
    Mol Biochem Parasitol; 2008 Apr; 158(2):202-7. PubMed ID: 18262292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Markers of drug resistance in relapsing colon cancer.
    Lazaris AC; Kavantzas NG; Zorzos HS; Tsavaris NV; Davaris PS
    J Cancer Res Clin Oncol; 2002 Feb; 128(2):114-8. PubMed ID: 11862483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II trial of CI-958 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
    Hoffman MA; Blessing JA; Nuñez ER
    Gynecol Oncol; 2001 Jun; 81(3):433-5. PubMed ID: 11371134
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correspondence re: C. F. M. Sier et al., Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers. Clin. Cancer Res., 6: 2333-2340, 2000.
    Gerhards S; Jung K; Koenig F; Daniltchenko D; Hauptmann S; Schnorr D; Loening SA
    Clin Cancer Res; 2001 Feb; 7(2):445-7. PubMed ID: 11234903
    [No Abstract]   [Full Text] [Related]  

  • 38. Determining and understanding the control of glycolysis in fast-growth tumor cells. Flux control by an over-expressed but strongly product-inhibited hexokinase.
    Marín-Hernández A; Rodríguez-Enríquez S; Vital-González PA; Flores-Rodríguez FL; Macías-Silva M; Sosa-Garrocho M; Moreno-Sánchez R
    FEBS J; 2006 May; 273(9):1975-88. PubMed ID: 16640561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recently elucidated energy catabolism pathways provide opportunities for novel treatments in hepatocellular carcinoma.
    Geschwind JF; Georgiades CS; Ko YH; Pedersen PL
    Expert Rev Anticancer Ther; 2004 Jun; 4(3):449-57. PubMed ID: 15161443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correspondence re: Y. Yamada et al., frequent beta-catenin gene mutations and accumulations of the protein in the putative preneoplastic lesions lacking macroscopic aberrant crypt foci appearance, in rat colon carcinogenesis. Cancer Res., 60: 3323-3327, 2000; and sequential analysis of morphological and biological properties of beta-catenin-accumulated crypts, provable premalignant lesions independent of aberrant crypt foci in rat colon carcinogenesis. Cancer Res., 61: 1874-1878, 2001.
    Pretlow TP; Bird RP
    Cancer Res; 2001 Oct; 61(20):7699-701. PubMed ID: 11606415
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.